Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Lexaria Bioscience Corp. (OTC: LXRP).

Full DD Report for LXRP

You must become a subscriber to view this report.


Recent News from (OTC: LXRP)

Venture Breakfast Bits, by 24/7 Market News
Venture Market News for September 7, 2018 Namaste Signs Cannabis Purchase Agreement With Tilray® VANCOUVER, Sept. 7, 2018 /CNW/ - Namaste Technologies Inc. ("Namaste" or the "Company") (TSXV: N) (FRANKFURT: M5BQ) (OTCMKTS: NXTTF) is pleased to announce that the Company has signed ...
Source: 24/7 Market News
Date: September, 07 2018 09:34
NetworkNewsBreaks - Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Announces Strategic Additions to Patent Portfolio
Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP), a drug delivery platform innovator, this morning announced strategic additions to its patent portfolio. Per the update, three new Australian patents were recently granted to Lexaria by the Australian Patent Office, bringing the company’...
Source: NetworkNewsWire
Date: September, 07 2018 08:30
Lexaria Receives Three Patent Grants and Two Notices of Allowance; Provides Patent Portfolio Guidance
(via TheNewswire) Kelowna, British Columbia / TheNewswire / September 7, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces strategic additions to its patent portfolio. Three new Aus...
Source: TheNewsWire
Date: September, 07 2018 06:30
Lexaria Bioscience Corp.'s (CSE: LXX) (OTCQX: LXRP) DehydraTECH Delivers Nicotine to Brain Faster
Ability to cross blood brain barrier – now confirmed – is significant for possible treatment of central nervous system diseases LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies LXRP completes formation of wholly owned subsidiary, Lexari...
Source: NetworkNewsWire
Date: September, 05 2018 13:15
Lexaria Warrant Exercises and Patent Share Awards
(via TheNewswire) Kelowna, British Columbia / TheNewswire / August 31, 2018 - Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the "Company" or "Lexaria"), a drug delivery platform innovator, announces it has received funds from the exercise of warrants. Lexaria...
Source: TheNewsWire
Date: August, 31 2018 17:01
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Viable and Effective Alternatives for Nicotine Delivery
Results from second in vivo study of 2018 a success DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes Clients are improving high-quality products through the enhancement of this drug delivery platform Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LX...
Source: NetworkNewsWire
Date: August, 31 2018 12:15
CannabisNewsBreaks - Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH(TM) Nicotine Study
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ ...
Source: CannabisNewsWire
Date: August, 31 2018 08:30
SeriousTraders Puts Spotlight on ATHC, AHELF, CIIX, CYDY, DNAX, FNNZF, FRSX, FTSSF, GRBX, LXRP, MCOA, NETE, NUGL, NUGS, REFG, PFSF, PHVAF, PRVCF, SGMD, SNNVF, TGODF, TMSR, TVTV, YGYI and ZNGY
Every month, SeriousTraders issues a newsletter to its subscribers jam packed with specialized articles; you won't miss an opportunity to hone your trading edge. Here are the 26 companies featured this month: Accelerated Technologies Holding Corp. (OTC: ATHC) is a full-service end-to-end...
Source: NetworkNewsWire
Date: August, 30 2018 08:55
NetworkNewsBreaks - Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Reports Additional Encouraging Results from DehydraTECH(TM) Nicotine Study
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) this morning announced further results from its recently completed second-generation study in 40 rats in addition to the partial results released earlier this month. The in vivo study evaluated the ability of the company’s DehydraTECH™ ...
Source: NetworkNewsWire
Date: August, 30 2018 08:30
Lexaria Bioscience Announces Positive Blood-Brain-Barrier Results
Lexaria's technology delivered 195% more nicotine across the blood-brain-barrier conceptually allowing for smaller micro doses in accordance with developing FDA policies. Lexaria's formulation was 4x faster at reaching its peak level in brain tissue than the non-enhanced control formul...
Source: ACCESSWIRE
Date: August, 30 2018 06:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.951.091.1110.9555,125
2018-12-131.041.061.161.0451,770
2018-12-121.121.151.221.1074,397
2018-12-111.301.121.301.10107,578
2018-12-101.131.241.251.06141,433

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1412,23755,12522.1986Cover
2018-12-135,43351,77010.4945Cover
2018-12-1226,63674,39735.8025Short
2018-12-1123,838107,57822.1588Cover
2018-12-1061,491141,32343.5110Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LXRP.


About Lexaria Bioscience Corp. (OTC: LXRP)

Logo for Lexaria Bioscience Corp. (OTC: LXRP)

Lexaria Bioscience Corp. has developed and out licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending and granted in over countries around the world and was granted its first patent in the USA in October. . Lexaria s technology provides increases of up to Ox in intestinal absorption rates more rapid delivery to the bloodstream with effects often with in minutes and important taste masking benefits for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

 

 

 

Current Management

  • Chris Andrew Bunka / CEO
  • John Docherty / President
  • Allan Horst Spissinger / CFO
  • Chris Andrew Bunka / Chairman
  • Nicholas Wilson Baxter / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • John Docherty /
  • William Edward McKechnie / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $96,478,755 - 03/09/2018
  • Authorized: 220,000,000 - 11/30/2016
  • Issue and Outstanding: 69,912,141 - 12/22/2017
  • Float: 42,152,370 - 02/28/2017

 


Recent Filings from (OTC: LXRP)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 13 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 12 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 07 2018

 

 


Daily Technical Chart for (OTC: LXRP)

Daily Technical Chart for (OTC: LXRP)


Stay tuned for daily updates and more on (OTC: LXRP)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: LXRP)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LXRP is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LXRP and does not buy, sell, or trade any shares of LXRP. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/